Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ103 Desensitization in Highly Sensitized Kidney Transplant Candidates
CTR20234137Phase 3Completed
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Dec 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ricefidase in Highly sensitized kidney transplant candidate (HS), sponsored by Shanghai Baoji Pharmaceutical. Primary endpoint: Proportion of patients with pre-existing donor-specific antibody (DSA) reduced to an acceptable negative transplantation level (phase II). Started Dec 2023; status: completed.
02
Drugs
ricefidase
03
Conditions
Highly sensitized kidney transplant candidate (HS)
Beyond the preview
Go deeper on CTR20234137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234137.